| Efficacy and Safety of SmofKabiven® Versus Hospital-Compounded All-in-One Parenteral Nutrition in Chinese Patients Undergoing Gastrointestinal Surgery: A Multicenter, Randomized, Active-Controlled, Phase III Trial.Nutr Cancer | PMID 40598717无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials.Dermatology | PMID 40602386PMC12500264 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy.Cancer Treat Res Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40700835无 PMCID | 2025 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.Cancer Treat Res Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40795416PMC12368867 | 2025 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Bowel Preparation for Colonoscopy: The Patient Point of View.Dig Dis | PMID 41021426PMC12668715 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of vilaprisan in Japanese women with fibroids: The Phase 3 ASTEROID 8 trial.Womens Health (Lond) | PMID 41059527PMC12511707 | 2025 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial.Front Endocrinol (Lausanne) | PMID 39991735PMC11842232 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study.Pediatr Dermatol | PMID 39529307PMC11950805 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.An Bras Dermatol | PMID 39648106PMC11962814 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLE.J Clin Lipidol | PMID 39843293无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR Outcomes trial.J Clin Lipidol | PMID 39939212无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.Pediatr Dermatol | PMID 39980188PMC11950803 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma -the IT-MATTERS study.Pathol Oncol Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图。 | PMID 40191245PMC11968324 | 2025 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Randomized Controlled Trial of the Behavioral Intervention for Increasing Physical Activity in Multiple Sclerosis Project: Fidelity Monitoring and Outcomes.Behav Med | PMID 39287190无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study.Front Immunol | PMID 40260247PMC12010144 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.CA Cancer J Clin | PMID 39970442PMC12061627 | 2025 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific.Travel Med Infect Dis | PMID 40120920无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study.Transpl Int | PMID 40458542PMC12127847 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension.Front Immunol | PMID 40469312PMC12135624 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of predicted lean body mass and fat mass with prognosis in patients with heart failure preserved ejection fraction.PLoS One | PMID 40446077PMC12124579 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.Front ImmunolAI 判定该论文不进入自动 KM 提取:The record reports a matching-adjusted indirect comparison (MAIC) analysis, not the results of a single human Phase III randomized controlled clinical trial. The underlying studies may be Phase III, but this publication synthesizes them indirectly. | PMID 40625746PMC12230042 | 2025 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.PLoS One | PMID 40554538PMC12186948 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The PD COMM Process Evaluation: Describing Interventions and Implementation in a UK Pragmatic Randomised Controlled Trial of Speech and Language Therapy for People With Parkinson's-Related Dysarthria.Int J Lang Commun Disord | PMID 40637984PMC12244302 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.PLoS One | PMID 40638707PMC12244563 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants.J Clin Lipidol | PMID 40713231无 PMCID | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Generic Intravenous Amisulpride (QLG2069) for the Prevention of Postoperative Nausea and Vomiting in Adults: A Phase III, Multicenter, Randomized, Placebo-Controlled Study.Drug Des Devel Ther | PMID 40923005PMC12414449 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial.PLoS One | PMID 40971945PMC12449008 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone.Gates Open Res | PMID 41080970PMC12508423 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information.Front Immunol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41142780PMC12546374 | 2025 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors.Front Immunol | PMID 41194933PMC12583077 | 2025 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Antibody response to tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b vaccines in allogeneic hematopoietic stem cell transplant adult recipients: A multicenter trial.PLoS One | PMID 41144397PMC12558451 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial.Headache | PMID 40586377PMC12638520 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis.Transpl Int入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41384277PMC12689443 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.Front Endocrinol (Lausanne)已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 2 张未列出。 | PMID 41404513PMC12702747 | 2025 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial.Front Immunol | PMID 41624863PMC12855095 | 2025 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.Hum Vaccin Immunother | PMID 38189360PMC10793708 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.Hum Vaccin Immunother | PMID 38509699PMC10962606 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.Hum Vaccin Immunother | PMID 38512394PMC10962622 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.Hum Vaccin Immunother | PMID 38523332PMC10965106 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.Hum Vaccin Immunother | PMID 38783590PMC11135872 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.Hum Vaccin Immunother | PMID 38838170PMC11253707 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis.Eur Heart J Cardiovasc Imaging | PMID 39172552PMC11687114 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months.Hum Vaccin Immunother | PMID 39445787PMC11508945 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes.Hum Vaccin Immunother | PMID 39535124PMC11562908 | 2024-Dec-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study.BMC Infect Dis | PMID 39736611PMC11684250 | 2024-Dec-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Attractive targeted sugar baits for malaria control in western Kenya (ATSB-Kenya): enrolment characteristics of cohort children and households.Malar J | PMID 39736740PMC11687092 | 2024-Dec-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Investigating the association between labor pain and cessation of breastfeeding.Sci Rep | PMID 39732915PMC11682455 | 2024-Dec-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.Blood | PMID 39316666PMC11738031 | 2024-Dec-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and ≥65 years): A post hoc analysis of Japanese Phase 3 clinical trials.Mod Rheumatol | PMID 39073574无 PMCID | 2024-Dec-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study.Mod Rheumatol | PMID 39073577无 PMCID | 2024-Dec-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |